ABX-IL8, functioning as a neutralizing antibody against CXCL8, can significantly inhibit the promoter activity and collagenase activity of MMP2 in melanoma cells, thereby diminishing tumor metastasis, reducing tumor angiogenesis, and augmenting tumor apoptosis (50). This evidence concerns the gene CXCL8 and neoplasm.